Biotica discovers and develops novel polyketide therapeutics to create new medicines for serious diseases. Biotica’s R&D pipeline is focused on optimised polyketide therapeutics for high-value indications. Biotica's compounds, generated using the proprietary novoPT™ technology, have unique chemistry and differentiated properties. Polyketides are the basis of more than 40 successful therapeutics in a wide range of diseases. They make excellent leads for drug discovery, with naturally high affinity to biologically relevant targets, including protein-protein interactions and other traditionally difficult targets. Biotica has formed successful partnerships with leading pharmaceutical companies, most recently Wyeth and GSK, based on its high-value projects. Projects are selected on three key criteria: market potential, clinical validation of the target and Biotica exclusivity.
View Top Employees from BioticaWebsite | http://www.biotica.com |
Revenue | $7.4 million |
Employees | 41 (9 on RocketReach) |
Founded | 1996 |
Phone | +44 1223 890539 |
Industry | Biotechnology Research, Manufacturing General, Manufacturing |
Competitors | Amphista Therapeutics Limited, Core Precision, Demuris Ltd, Isomerase Therapeutics Ltd. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Biotica employee's phone or email?
The Biotica annual revenue was $7.4 million in 2024.
Veselina Kisselkova is the Owner of Biotica.
9 people are employed at Biotica.
The NAICS codes for Biotica are [32, 325, 3254].
The SIC codes for Biotica are [28, 283].